Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Vertex Pharmaceuticals (Nasdaq ... It was the first company to receive FDA approval, in December 2023, for Casgevy – a genome-edited cell therapy for sickle-cell disease and another blood ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA approved Vertex Pharmaceuticals’ gene therapy Casgevy for treating beta thalassemia, an inherited blood disease that leads to low levels of functioning hemoglobin. Last month ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

So the amount of the benefit to Vertex will depend on the rate of ALYFTREK's growth and switching during the year. Offsetting that is margin pressure from CASGEVY, which is very early in its ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Biotech company Vertex Pharmaceuticals (NASDAQ ... the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base ...

Vertex Pharmaceuticals (Nasdaq ... patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...